Tyra Biosciences develops precision molecules targeting acquired resistance pathways in oncology, utilizing a proprietary approach to drug design. The company aims to enhance treatment efficacy for cancer patients by addressing the limitations of existing therapies that fail due to resistance mechanisms.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing cancer therapies often become ineffective due to the development of acquired resistance pathways in tumors. These resistance mechanisms limit the long-term efficacy of treatments and lead to disease progression in cancer patients.
Solution
Tyra Biosciences is developing a portfolio of precision oncology medicines designed to overcome acquired resistance in cancer. Their approach focuses on designing molecules that specifically target and inhibit the signaling pathways that drive resistance, thereby restoring sensitivity to treatment. By addressing the root causes of resistance, Tyra aims to create more durable and effective therapies for patients with various types of cancer. This strategy seeks to improve patient outcomes by extending the duration of response and preventing disease relapse.
Target Audience
The primary target audience includes cancer patients with acquired resistance to existing therapies, as well as oncologists and researchers seeking more effective treatment options.
Features
- Proprietary drug design platform for generating highly selective kinase inhibitors.
- Focus on targeting specific resistance mutations and bypass mechanisms in oncology.
- Development of small molecule therapeutics with optimized pharmacokinetic properties.
- Clinical programs targeting a range of solid tumors and hematologic malignancies.